endothelial nitric oxide synthase and diuretics, the α-adducin gene and diuretics, the α-subunit of G protein and β-adrenoceptor antagonists, and the ACE gene and angiotensin II type 1 (AT1) receptor antagonists. Other studies found an interaction between ACE inhibitors and the ACE insertion/deletion (I/D) polymorphism, which resulted in differences in AT1 receptor mRNA expression, left ventricular hypertrophy and arterial stiffness between different genetic variants. Also, drug-gene interactions between calcium channel antagonists and ACE I/D polymorphism regarding arterial stiffness have been reported. Unfortunately, the quality of these studies is quite variable. Given the methodological problems, the results from the candidate gene studies are still inconclusive and further research is necessary.
Hypertension is a major public health hazard sion. From family, twin and adoption studies it has because of its high prevalence, which is approxi-been estimated that 30-60% of the variation in mately 20% of the adult population in most devel-blood pressure between individuals is caused by oped countries, [1] and its high risk of cardiovascular genetic factors. [8] However, there is a small propordiseases. Despite the availability of a variety of tion of familial forms of hypertension that have a effective antihypertensive drugs, inadequate control single gene (Mendelian) inheritance pattern. These of blood pressure is common in hypertensive pa-include: [9] [10] [11] tients, and is responsible for a large proportion of • apparent mineralocorticoid excess cardiovascular disease in the population. [2] [3] [4] The • glucocorticoid remediable aldosteronism average response to antihypertensive drugs is simi-• hypertensive forms of congenital adrenal hyperlar across different classes of antihypertensives. For plasia example, in the Veterans Affairs study, [5] a random-• Liddle's syndrome ised placebo-controlled clinical trial in which pa-
• pseudohypoaldosteronism type II/Gordon's syntients were randomly allocated to six different drugs drome or placebo, 31.7% of all hypertensive patients who
• early-onset, autosomal dominant hypertension were allocated to monotherapy with an antihyperwith severe exacerbation in pregnancy tensive drug failed to achieve a normal diastolic
• Bardet-Biedl syndrome types 2 and 4. blood pressure. When the initial treatment failed, 85 .9% of these patients were randomised to another Pharmacogenetics focuses on the extent to which antihypertensive which failed in 37.8% of these variability in genetic make-up is responsible for the patients. [5] Although, the currently used 'trial and observed differences in therapeutic response and error' approach to antihypertensive drug therapy can adverse reactions between patients. [6, 7] In other be efficient in treating high blood pressure, it is not words, pharmacogenetics studies the interaction befeasible with regards to long-term effects such as tween drugs and genes, where interaction is defined myocardial infarction (MI) and stroke. Important as being present if the joint effect of a drug and factors in interpreting the variability in outcome of genetic polymorphism is greater than the sum (addidrug therapy include the patient's general health, tive scale) or product (multiplicative scale) of the prognosis, disease severity, quality of drug prescrib-individual effects of the drug and the genetic polying and dispensing, compliance with prescribed morphism. The purpose of pharmacogenetics is to pharmacotherapy and the genetic profile of the pa-understand the effects of genetic diversity on human tient. [6, 7] response to drugs and other foreign substances and Multiple susceptibility genes and the environ-to use this information to avoid the occurrence of ment explain the phenotype of essential hyperten-therapeutic failure and adverse drug reactions in susceptible persons. [12] Drugs that are more specific tends the previous overviews and discusses some of for functional characteristics associated with an in-the reasons for inconsistent results regarding drugdividual patient's polymorphism may contribute to a gene interactions between genetic polymorphisms better response and reduced toxicity of pharmaco-and antihypertensive drug therapy. Studies were therapy.
identified in the Medline database from 1966 to October 2003 by combinations of keywords 'antiGenetic polymorphisms may influence drug reshypertensive drug', 'genetics', 'polymorphism' and ponse in three ways. [13] by checking the references of all identified papers.
Through variation in pharmacokinetics that may
All studies that reported data on genetic polymorphpertain to absorption, but is mostly explained by isms and response to antihypertensive drug therapy altered metabolic clearance. Many pharmacokinetic were included. Response to antihypertensive drugs drug-gene interactions are related to the cytochrome was not pre-specified and could include blood pres-P450 (CYP) enzyme system. [14] The majority of sure response, change in left ventricular mass these enzymes are located in the endoplasmic reticu-(LVM), risk of MI and stroke, and other cardiolum of the hepatocytes. This enzyme system can be vascular effects. modulated by genetic polymorphisms, causing some individuals to be poor (slow) metabolisers and 1. Candidate Gene Studies and others to be extensive (rapid) metabolisers. This is Antihypertensive Drugs the case for many calcium channel antagonists that are metabolised by CYP3A4, many lipophilic β-Thirty-six studies were found on the potential adrenoceptor antagonists metabolised by CYP2D6, gene-drug interaction between genetic polymorphand losartan and irbesartan metabolised by isms and antihypertensive drugs. Details of these CYP2C9. [15] However, it is unlikely that pharmaco-studies are given in One of the first polymorphisms examined for signal transduction molecules, which are relevant to blood pressure response in patients treated with dithe pharmacodynamics of drugs.
uretics was the G460W (a Gly to a Trp substitution 3. Through genes that are in the causal pathway of at residue 460) α-adducin polymorphism. [21, 22] The the disease and are able to modify the effects of human α-adducin 460W allele can be considered as drugs. It is also important to realise that most of the a candidate gene for hypertension, because it may variation in blood pressure can be explained by a affect blood pressure by increasing renal tubular pharmacodynamic, rather than by pharmacokinetic, reabsorption of sodium through the activation of mechanism. [16] This is most apparent in studies in Na + , K + -ATPase (adenosine triphosphatase). Linkwhich pharmacokinetic and pharmacodynamic as-age and association studies, performed with markers sessments are available in the same subjects, and in mapping in the region (loci) of the α-adducin locus which inter-subject variability can be expressed as a and with the G460W α-adducin polymorphism, recoefficient of variation.
spectively, yielded positive associations. [21] ComFour previous review articles presented pharma-pared with hypertensive patients who are homozycogenetic concepts relevant to antihypertensive drug gous for the 460G wild-type allele, hypertensive therapy. These articles included a brief overview of patients carrying at least one 460W allele have a less candidate gene studies with respect to blood pres-steep pressure natriuresis slope. This means that sure response and other cardiovascular responses to they need a higher arterial pressure to excrete the antihypertensive drug therapy. [17] [18] [19] [20] Our review ex-same amount of sodium after saline infusion. [55] 
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Calcium Moreover, they have lower plasma renin activity, [21] tion of 12mm Hg in mean blood pressure.
[24] In another study the 460W allele was associated with a enhanced proximal tubular reabsorption, [56] and a lower risk (odds ratio [OR] 0.49; 95% CI 0.32, 0.77) more pronounced blood pressure decrease after of MI and stroke in diuretic users compared with acute sodium depletion or long-term diuretic treatusers of other antihypertensive drug therapies.
[23]
ment. [21] The 460W allele of the α-adducin gene is associated with a higher affinity for the Na + , K + -Recently, the ACE insertion/deletion (I/D) polyATPase pump than the 460G allele.
[57] This last morphism was investigated for its role in blood finding is particularly relevant because the same pressure response to a diuretic (hydrochlorothiazide functional protein alteration has been demonstrated 25mg). In this study a significant association was in both the rat and human 'hypertensive' α-adducin found between ACE I/D polymorphism and resvariant, suggesting that the protein plays a crucial ponse to hydrochlorothiazide. Hypertensive patients with the I/I genotype had a mean arterial pressure role in Na + /K + metabolism. [57, 58] In two trials, the reduction of approximately 10mm Hg and those 460W allele was associated with a greater blood with the D/D genotype a reduction of 3.8mm Hg.
[24]
pressure reduction in response to treatment with diuretics. In the heterozygous (G/W) hypertensive A third polymorphism that may influence the patients a mean blood pressure decrease of effect of a diuretic is the 825C/T (cytosine into a 14.7 ± 2.2mm Hg was found versus 6.8 ± 1.4mm Hg thymine) polymorphism (exon 10) of the gene enin the homozygous (G/G) hypertensive pa-coding for the β 3-subunit of the G-protein. The Gtients. [21, 22] Recently, a second group of researchers proteins mediate signal transduction across cell also found an interaction between mean arterial membranes. [59] The 825T allele of the β3-subunit of pressure (diastolic blood pressure + [systolic blood the G-protein polymorphism has been related to an pressure -diastolic blood pressure]/3) reduction and RNA splice variant that results in the deletion of the G460W polymorphism. Homozygous (G/G) hy-nucleotides 498-620 of exon 9 and structural pertensive patients had a reduction of 6mm Hg and changes in the β-subunit. [60] Moreover, an enhanced patients with at least one 460W allele had a reduc-signal was observed in lymphoblast lines from hy-pertensive individuals carrying the 825T allele, [59] the other genotype groups. Additionally, their prewhich suggests that this genetic variation may in-viously reported interaction with ACE gene [26] could deed affect signal transduction. In one trial, a posi-also not be replicated with this larger sample size. [25] tive association was found between the 825T allele Recently, an alternatively spliced transcript of and the effect of hydrochlorothiazide on blood pres-the β3-subunit of the G-protein referred to as Gβ3S2 sure. Mean declines in systolic and diastolic blood was identified. Transcripts of the Gβ 3S2 lack 129 pressures were 6 ± 2 and 5 ± 1mm Hg greater in TT base pair of coding sequence of the β3-subunit of the than in CC homozygous patients, respectively. [27] G-protein.
A close association between Gβ3S2 exHowever, with a larger sample size (585 vs 387 in pression and T-allele status of the 825C/T polymorthe earlier study [27] ) the investigators could not repliphism of the β3-subunit of the G-protein was found. cate these results. [25] Instead, they found an interThe data suggest that Gβ3S2 is a biologically active action between thiazides and the 298E allele of variant of the β-subunit of the G-protein, which may nitric oxide synthase gene on diastolic blood presplay a role in the manifestation of the complex sure. Hypertensive patients homozygous for the E phenotype associated with the 825C/T polymorallele had a diastolic blood pressure reduction of phism.
[61]
8.6 ± 0.4mm Hg compared with 7.1 ± 0.6mm Hg for c The M235T and T174M polymorphisms of the angiotensinogen gene are counted as two studies.
d Two studies found an association with insertion allele, one study with deletion allele.
e Only DBP.
f Compared with other antihypertensive therapies.
A/N = associated/not associated; AS = arterial stiffness; AT1R mRNA = angiotensin II type 1 receptor messenger RNA expression; BP = blood pressure; DBP = diastolic blood pressure; HR = heart rate; LVH = left ventricular hypertrophy; LVM = left ventricular mass; MI = myocardial infarction; SBP = systolic blood pressure; St = stroke.
A polymorphism of the α-adducin gene may be In patients with nondiabetic nephropathy, the used to identify patients with hypertension who are presence of the ACE D allele was associated with a salt sensitive and respond relatively well to treat-reduction of glomerular filtration. [47] Another drugment with a diuretic. Nevertheless, two studies did gene interaction with the ACE D allele was observed not find an association between salt sensitivity and in patients with chronic heart failure. In this this gene in young men [62] or the general popula-study, [48] treatment with a β-adrenoceptor antagonist tion. [63] The β3-subunit of the G-protein was also was associated with a decreased need for heart transproposed as a candidate gene, but Ciechanowicz et plantation. al. [64] could not find an association between polyThe A (adenine) into a C (cytosine) transversion morphism of the α-adducin gene and salt sensitivity at nucleotide position 1166 is located in the 3′un-of blood pressure. Furthermore, it has been suggest-translated region of the AGTR1 gene on chromoed that polymorphisms of the angiotensin II type 1 some 3q21-q25. Some studies have shown that it receptor gene (AGTR1) and the γ-subunit of the was associated with hypertension, [68, 69] left ventricuepithelial Na + -channel are also associated with salt lar hypertrophy (LVH), [70] coronary heart dissensitivity.
[65,66] However, Giner et al. [67] could not ease, [71] MI, [72] and progression of diabetic nephropfind an association. Whether genetic polymorph-athy.
[73] The 1166A/C polymorphism of the AGTR1 isms that are associated with salt-sensitivity also gene was, however, not related to variation in blood modify the response to diuretics remains to be inves-pressure response or degree of LVH during β-adretigated.
noceptor antagonist therapy in small groups of hypertensive patients.
[28-30]
β-Adrenoceptor Antagonists
Recently, Liljedahl et al. [35] tested a microarraybased minisequencing system on DNA samples of In only two of 11 studies was a drug-gene inter-97 hypertensive patients, of whom 49 were treated action found between a genetic polymorphism and with atenolol. They genotyped 74 single nucleotide reduced blood pressure response to a β-adrenoceptor polymorphisms (SNPs) in 25 genes that were inantagonist. [33, 37] This reduced response was attribut-volved in blood pressure regulation. This group of ed to a FokI +/-polymorphism encoding for the α-researchers found a drug-gene interaction between subunit of the G-protein. Good responders (62.5% atenolol and several genes which resulted in a had a FokI + allele) had a mean arterial blood change in blood pressure, including: pressure decrease of >15mm Hg and poor respond-• 40G/A polymorphism of the endothelin receptor ers (41.7% had a FokI + allele) had a decrease of type B gene <11mm Hg. [37] The α-subunit of each heterotrimeric • 278G/T and 1817G/A polymorphism of the ad-G-protein contains the guanine nucleotide-binding renergic α1a-receptor gene site, which has intrinsic guanosine triphosphatase
• 1342G/C and 1309G/A polymorphism of the adactivity and confers the functional specificity on renergic β2-receptor gene each G-protein that allows it to discriminate among • 498G/A and 2996A/G polymorphism of the enmultiple receptors and effectors. In the cardiodothelial nitric oxide synthase gene vascular system, the α-subunit of the G-protein
• 110A/G polymorphism of the lipase hepatic couples β1-and β2-adrenoceptors in order to stimugene. late cyclic adenosine monophosphate (cAMP) production. Johnson et al. [33] found an interaction beHowever, this study [35] included only a small tween β1-adrenergic receptor and metoprolol. Pa-number of patients and was focused on the applicatients homozygous for arginine at codon 389 had a bility of the minisequencing system rather than on nearly 3-fold greater reduction in daytime diastolic finding drug-gene interactions. Because of the large blood pressure compared with those who carried the number of SNPs tested without adjustment for mulvariant allele.
tiple testing and the small number of patients, this study could have resulted in a large number of false-tension, [40, 43] greater reduction of glomerular filtrapositive and false-negative associations. tion in diabetic and nondiabetic patients, [44, 47] and less reduction of proteinuria in patients with nondiabetic nephropathy (primarily combined with
ACE Inhibitors
a high excretion of salt). [74] Most studies on interactions between ACE inhibIn two studies, the interaction between the itors and genetic polymorphisms have concentrated 1166A/C polymorphism of the AGTR1 gene and the on the renin-angiotensin system (RAS). One of the response to ACE inhibitors was investigated. In a steps of the RAS is the expression of angiotensi-small study, no interaction was found. [38] In a larger nogen precursor in the liver. In response to lowered study, the C allele was associated with greater reblood pressure it is cleaved by the enzyme renin. duction of arterial stiffness and blood pressure by The resulting product, angiotensin I, is then cleaved ACE inhibition. [46] Patients with the AA genotype by ACE to generate the physiologically active had a blood pressure reduction of approximately enzyme angiotensin II. This protein is involved in 6mm Hg and those with AC/CC genotype had a maintaining long-term blood pressure and in the reduction of approximately 14mm Hg. [46] pathogenesis of essential hypertension.
In one study, no drug-gene interaction was found nine into a threonine) polymorphism of the angiotensinogen gene.
[28] However, in a larger study an Only one group has investigated the role of geinteraction was found.
[38] In this study, the reduction netic polymorphisms and the response to an angioin systolic blood pressure was 20 ± 3mm Hg in pa-tensin II type 1 (AT1) receptor antagonist (irbesartients with TT genotype compared with 22 ± 2mm tan). [29, 30, [34] [35] [36] The 174M allele of the angiotensiHg in patients with MT genotype and 13 ± 4mm Hg nogen gene was associated with a positive effect of in patients with the MT and MM genotype. The irbesartan on LVH. No interactions were found bereduction in diastolic blood pressure in patients car-tween the M235T polymorphism of the angiotensirying the TT allele was 11 ± 3mm Hg compared nogen gene or the -344C/T (cytosine to a thymine) with 14 ± 2mm Hg in patients with MT genotype polymorphism of the aldosterone synthase gene and 8 ± 2.5mm Hg in patients with the MM geno-(CYP11B2) and irbesartan on reduction of type. [38] LVH. [29, 30, 34] However, the -344T allele of the aldoMost studies have concentrated on investigating sterone synthase gene was associated with an inthe association between the I/D polymorphism (in-creased reduction of systolic blood pressure after tron 16) of the ACE gene and the response to an treatment with the AT1 receptor antagonist. Patients ACE inhibitor. In one study, [39] a greater blood with the TT genotype had a mean reduction in blood pressure reduction with ACE inhibitor therapy was pressure of 21 ± 19mm Hg compared with observed in subjects with the D allele. In this study, 14 ± 18mm Hg in patients with TC genotype and the reduction in systolic blood pressure in patients 0 ± 17mm Hg in patients with CC genotype. [34] In with the DD genotype was 5.6 ± 3.1mm Hg com-contrast, the I allele of the ACE gene was associated pared with 3.1 ± 1.1mm Hg with the II genotype, with a reduction of diastolic blood pressure. Patients and 3.6 ± 2.2mm Hg and with the ID genotype. The with the II genotype had a reduction of reduction in diastolic blood pressure in patients with 18 ± 12mm Hg compared with 8 ± 11mm Hg in pathe DD genotype was 8.9 ± 6.0mm Hg compared tients with ID genotype and 6 ± 9mm Hg in patients with 5.5 ± 3.4mm Hg with the II genotype with DD genotype. [29] Aldosterone synthase is a key 5.8 ± 4.0mm Hg with the ID genotype. In the other rate-limiting enzyme for the biosynthesis of aldostudies, the insertion allele was associated with a sterone. The -344C/T polymorphism is associated reduced regression of LVH in patients with hyper-with elevated plasma aldosterone concentration through increased aldosterone synthesis. [75] These tors regarding blood pressure response. The most results suggest that the -344T allele is functionally promising result was the interaction between the associated with increased sodium reabsorption and G460W allele of the α-adducin gene and blood thereby maintains blood pressure at a higher level pressure reduction and risk of MI and stroke in due to volume expansion.
response to diuretics. However, these results need to be replicated before definitive conclusions can be Liljedahl et al. [35] tested a microarray-based made. minisequencing system on DNA samples of 97 hypertensive patients of whom 48 were treated with 2.1 Study Power irbesartan. They found that lowering of blood pressure by irbesartan was modified by several
It is known that it may be problematic to demonpolymorphisms, including: strate linkage or association consistently. For exam-
• 1449A/G polymorphism of the apolipoprotein A ple, some groups were able to confirm an associa-• 267C/T polymorphism of the CYP, family 11, tion between hypertension and the M235T polymorsubfamily B, polypeptide 2 gene (CYP11B2) phism, while others could not. [76] [77] [78] A meta-analysis
• 40G/A polymorphism of the endothelin receptor of 5500 subjects reported a significant (OR 1.2;
type B gene p < 0.0001) but weak association between this poly-
• 498G/A polymorphism of the endothelial nitric morphism and hypertension. [79] This is most likely oxide synthase gene the same for studies investigating the role of genetic [25]
Calcium Channel Antagonists
found no interaction between the ACE gene and β3-subunit of the G-protein and the effect of hydroThe influence of genetic polymorphisms on calchlorothiazide on blood pressure response, in concium channel antagonists has been examined in trast to their previous reported finding of an associathree studies. In one study, an interaction was obtion with a smaller sample size. [26, 27] The sample served between calcium channel antagonists and the size in the studies investigating antihypertensive ACE gene: patients with the I allele had a reduced drug-gene interactions in hypertensive patients expression of AT1 receptor mRNA.
[31] Another ranged from 40 to 1048 persons. However, 71% of study found a drug-gene interaction with the A allele the studies had less than 100 patients, which is not of the 1166A/C polymorphism of the AGTR1 gene, sufficient for conclusive results when, besides a which leads to greater reduction of arterial stiffgenetic factor, an interaction is also investigated. ness. [46] A drug-gene interaction between the The number of patients needed to detect drug-gene M235T allele of the angiotensinogen gene and calciinteractions depends on the outcome studied (e.g. um channel antagonists could not be demonstrated continuous versus categorical), the contrast between regarding blood pressure response. [28, 46] responders and nonresponders in different genotype 2. Potential Reasons for groups (the amount of interaction), and the precision Inconsistent Findings of the measurements. [80, 81] Most of the studies exhibited inconsistent find-
Genetic Diversity between Populations
ings and did not yield conclusive results. In one [39] of four studies, [28, 38, 39, 43] for example, an interaction Genetic diversity between populations can hinder was found between the ACE gene and ACE inhibi-replication of results. Gene variants that were select-ed during evolution to conserve salt, for example, blood pressure, while Turner et al. [25] used systolic may play a larger role in hypertensive patients with and diastolic blood pressure separately. ancestors from Africa. [18] In a study where the disease-causing allele is more prevalent, it might be 2.4 Genetic Polymorphism and easier to find an interaction. One example which Disease-Causing Factors was investigated for antihypertensive drug-gene interaction is the frequency of the I allele of the ACE Most of the examined polymorphisms are probgene which is different between Asian and Cauca-ably not the disease-causing factors. [49] An example sian populations, i.e. 62% and 50%, respective-is the M235T polymorphism of the angiotensinogen ly. [28, 38, 39, 43] gene. There is now evidence that an A-for-G nucleotide substitution in the promoter region of the angiotensinogen gene 6 nucleotide upstream from the
Different Study Design
start site of transcription is the functional mutaThere are often different inclusion criteria for tion. [82, 83] The A substitution alters the binding of a different study populations. If, for example, one nuclear protein, resulting in increased gene transtudy only included patients with severe hyperten-scription compatible with increased angiotensision, it is possible that these patients have a genetic nogen levels. Fortunately, it has been suggested that profile which differs from moderate hypertensive the -6G/A allele is nearly in complete linkage disepatients examined in another study. This might be quilibrium (LD) with the M235T polymorthe case when the study of Stavroulakis et al. [39] phism. [79, 84] The same holds for the I/D polymor-(systolic blood pressure ≥140mm Hg and/or diastol-phism in the ACE gene. The I/D polymorphism ic blood pressure ≥90mm Hg) is compared with predicts approximately half of the interindividual Hingorani et al. [38] (systolic blood pressure >160mm variability of ACE levels in serum [85, 86] and tisHg or diastolic blood pressure >90mm Hg). Further-sue. [87] Thus, the probability that the ACE gene is not more, differences in treatment regimen were found in linkage equilibrium with the functional polymorbetween these studies. Both studies had a 4-week phism is considered very small.
[86, 88, 89] washout period, but in one study patients were given fosinopril 20mg once daily [39] (defined daily dose 3. Considerations in the Design of [ddd] equivalent = 1.33) while in the other study, [38] Pharmacogenetic Studies patients were given captopril 50 mg/day or enalapril 10 mg/day or lisinopril 10 mg/day or perindopril There are several ways to design studies to inves-4 mg/day (all ddd equivalent = 1). Another influence tigate interactions between antihypertensive drugs may be the variation in duration of therapy in differ-and genetic polymorphisms. All studies performed ent studies. The duration of therapy ranged from 15 to date investigated (allelic) polymorphisms. This days to 7 years in studies which focused on anti-sort of study provides the most powerful approach to hypertensive drug-gene interactions in hypertensive identify genes of small effect in complex traits, [90] patients.
because the markers that are used are either very Different results may be explained by the use of close to the susceptibility locus or lie in the gene of different study designs, such as experimental (e.g. interest itself. It is difficult to perform a linkage randomised clinical trial) and observational (e.g. study, because a high number of patients would be cohort and case-control) studies. In observational needed and only relatives who use the same antistudy designs, for example, confounding may be a hypertensive drugs can be included. In the future, problem (e.g. population stratification).
genome-wide association studies using SNPs will Another potential explanation for different re-become available, which will make it possible to use sults relates to the definition of outcome. For in-unrelated cases and controls to map regions of the stance, Scairrone et al. [24] used the reduction in mean genome, and eventually the whole genome.
It is possible to consider different endpoints association between the genetic variant and the outcome that can occur when the variant is associated when investigating hypertension. For example, studwith an unknown risk factor which varies by ethniciies could consider long-term outcomes such as MI ty. Population stratification may also be important in and/or stroke, intermediate-term outcomes such as drug response. For instance, African Americans atherosclerosis and/or LVH, or short-term outcomes may react differently to a specific antihypertensive such as blood pressure. Another option is to investidrug class compared with Caucasians. [92] [93] [94] [95] The imgate adverse effects of antihypertensive drugs or pact of population stratification is, however, not yet adherence to antihypertensive medication. Moreclear. Some conditions must be met before a subover, there are several potential inclusion criteria stantial bias occurs: (i) there must be substantial and there is no clear indication whether it is, for variation across ethnicities in the allele frequency of instance, best to choose mild or severe hypertension.
the relevant gene; (ii) there must be substantial It is important to consider the appropriate group of variation in disease rates; (iii) allele frequencies controls, because a strong difference in response can must correlate with adjusted disease rates between result in spurious drug-gene interactions.
ethnic groups; and (iv) adjustment for ethnicity must The number of markers and the question which not reduce the relevant effect. [96] At present it is still markers an investigator wants to test also need to be unclear whether population stratification biases reconsidered. There are biallelic (SNPs and deletion/ sults in a substantial way. [91, 97] To minimise the insertion polymorphisms) and microsatellite mark-effect of population stratification, a solution could ers (tandem repeats). Biallelic markers are relatively be typing additional markers unrelated to the outless polymorphic, but they are more abundant and come, [96] or match for ethnicity. [97, 98] accessible. The number of markers depends on whether there is significant LD in the candidate gene 4. Future Prospects in the study population. LD occurs when two particular alleles at loci on the chromosome go together Although there are many difficulties to overmore often than may be expected from independent come, pharmacogenetics may yield successful stratsegregation in a population. LD can be determined egies to optimise drug therapy. Several potential with a small pilot sample. This can help to optimise candidate genes are currently under investigation for marker selection and provide information for their potential to modify response to antihypertenhaplotype analysis. [91] Genotyping more markers sive drugs. Findings from previous studies require gives more information and thus more power. It is, conformation in other studies to be able to make nonetheless, more expensive and time consuming, definitive conclusions about current positive drugand the sample size has to be increased because gene interactions. It is also important that research more genotypes groups are identified. When more groups collaborate more in order to facilitate the markers are tested, adjustment should be made for conduct of a meta-analysis for conclusive results. multiple testing. It is best to investigate only candi-With the development of efficient methods for date genes, which can be linked to a biological analysing massive amounts of data, pharmacogenetsystem. For antihypertensive response, for instance, ic studies may eventually lead to the optimisation of the genes in the renin-angiotensin-converting antihypertensive drug therapy based on genetic enzyme are prominent, and other regulatory mech-profiles of patients. anisms of pressure-natriuresis are important because of their role in blood pressure homeostasis.regulation may not be excluded by negative association study.
